



## ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

February 10, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 10, 2022-- [ImmunoGen Inc.](#) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results. Management will also provide a brief update on the business.

### CONFERENCE CALL INFORMATION

To access the live call by phone, dial (877) 621-5803; the conference ID is 5566069. The call may also be accessed through the Investors and Media section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the call, a replay will be available at the same location.

### ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at [www.immunogen.com](http://www.immunogen.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220210005022/en/): <https://www.businesswire.com/news/home/20220210005022/en/>

### INVESTOR RELATIONS AND MEDIA

ImmunoGen  
Courtney O'Konek  
781-895-0600  
[courtney.okonek@immunogen.com](mailto:courtney.okonek@immunogen.com)

OR

FTI Consulting  
Robert Stanislaro  
212-850-5657  
[robert.stanislaro@fticonsulting.com](mailto:robert.stanislaro@fticonsulting.com)

Source: ImmunoGen Inc.